Reckitt Benckiser Stock News

Like-for-like net revenue in North America fell 1.3%, but the company anticipates a rebound from Lysol and North America in the fourth quarter.

Dettol maker Reckitt lowered ​its annual revenue ‌forecast on Tuesday and reported revenue growth ​below analyst ​expectations in the third ⁠quarter, hampered by ​a challenging consumer ​environment

UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.

A change in Reckitt's sales tactics led to 12 consecutive quarters of double-digit sales growth in the country.

Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer health and hygiene company, faces differing forecasts from UBS and Jefferies ahead of its third-quarter trading update, with both brokers retaining ‘buy' ratings but taking different views on near-term growth. UBS expects group like-for-like sales growth of 3.7% in the third quarter, broadly in line with Visible Alpha consensus, w...

Plus, the U.S. is pressuring Mexico over AI-hardware exports, and consumers have paid an extra $107 billion for fuel since the Iran war started.

Shares in Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods company behind Dettol and Nurofen, rose over 4% on Tuesday as investors digested a legal win for its Mead Johnson unit and a JP Morgan upgrade to overweight. The upgrade came in a wider note on European consumer staples published by JP Morgan analyst Celine Pannuti on Tuesday.